- Joy, Mary T;
- Joy, Mary T;
- Ben Assayag, Einor;
- Shabashov-Stone, Dalia;
- Liraz-Zaltsman, Sigal;
- Mazzitelli, Jose;
- Arenas, Marcela;
- Abduljawad, Nora;
- Kliper, Efrat;
- Korczyn, Amos D;
- Thareja, Nikita S;
- Kesner, Efrat L;
- Zhou, Miou;
- Huang, Shan;
- Silva, Tawnie K;
- Katz, Noomi;
- Bornstein, Natan M;
- Silva, Alcino J;
- Shohami, Esther;
- Carmichael, S Thomas
We tested a newly described molecular memory system, CCR5 signaling, for its role in recovery after stroke and traumatic brain injury (TBI). CCR5 is uniquely expressed in cortical neurons after stroke. Post-stroke neuronal knockdown of CCR5 in pre-motor cortex leads to early recovery of motor control. Recovery is associated with preservation of dendritic spines, new patterns of cortical projections to contralateral pre-motor cortex, and upregulation of CREB and DLK signaling. Administration of a clinically utilized FDA-approved CCR5 antagonist, devised for HIV treatment, produces similar effects on motor recovery post stroke and cognitive decline post TBI. Finally, in a large clinical cohort of stroke patients, carriers for a naturally occurring loss-of-function mutation in CCR5 (CCR5-Δ32) exhibited greater recovery of neurological impairments and cognitive function. In summary, CCR5 is a translational target for neural repair in stroke and TBI and the first reported gene associated with enhanced recovery in human stroke.